Matrix Pharmacorp Private Ltd, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is DEXLANSOPRAZOLE SESQUIHYDRATE, with a corresponding US DMF Number 24503.
Remarkably, this DMF maintains an Active status since its submission on December 21, 2010, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 22, 2013, and payment made on November 23, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II